Egypt Liver Diseases Therapeutics Market Report 2022 to 2030

Egypt Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Egypt Liver Disease Therapeutics market will reach a value of $113 Mn from $65 Mn in 2022, growing at a CAGR of 7.2% during 2022-2030. Liver Disease Therapeutics in Egypt is dominated by domestic pharmaceutical companies such as Pharco Pharmaceuticals, Delta Pharma, and EIPICO. The Liver Disease Therapeutics market in Egypt is segmented into different types of disease and different therapy types. Some of the significant factors affecting the Egypt Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10EGPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Vishwa Modhia

Buy Now

Egypt Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Egypt Liver Disease Therapeutics market will reach a value of $113 Mn from $65 Mn in 2022, growing at a CAGR of 7.2% during 2022-2030.

Egypt is a lower middle-income, developing country in North Africa that borders the Red Sea and the Mediterranean Sea. According to the latest WHO data published in 2020 Liver Disease Deaths in Egypt reached 60,122 or 11.20% of total deaths. The age-adjusted Death Rate is 93.37 per 100,000 population ranks Egypt 1^st in the world.

The Egyptian Ministry of Health has recently suggested a new national strategy to control the HCV pandemic in Egypt with a higher capital fund and with help from the WHO as well as other agencies. Citation19 This programme, dubbed "The Plan of Action for the Prevention, Care, and Treatment of Viral Hepatitis 2014-2018," pushed sofosbuvir. Egypt's government spent 4.4% of its GDP on healthcare in 2020.

Egypt Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

In Egypt, various care programmes have been designed to combat liver disorders such as schistosomiasis and viral hepatitis. Hepatitis A is one of the most common diseases in Egypt. Viral liver disease is caused by the hepatitis A virus. Interferon treatment was prohibitively expensive, especially for Egypt's primarily impoverished patient population, resulting in irregular access to treatment. With the medicine producer, the Egyptian government successfully negotiated considerable price reductions for direct-acting antiviral (DAA) drugs. Egypt reduced prices even more by allowing local, generic competition. This enabled the Egyptian government to tackle the outbreak on a scale that would have been impossible otherwise. These aspects could boost Egypt's Liver Disease Therapeutics market.

Market Restraints

One of the most pressing issues for the Egyptian people, however, is available of these medical therapies, especially given that Egypt's HCV pandemic is predominantly socioeconomic in character. Some innovative medicines have demonstrated an efficacy of higher than 90%. However, the expense of these new drugs is a significant obstacle to their availability. With a growing population, limited resources, and a lack of infection control techniques, Egypt still confronts serious disease management concerns today. These factors may deter new entrants into the Egypt Liver Disease Therapeutics market.

Competitive Landscape

Key Players

EIPICO: Egyptian International Pharmaceutical Industries Company (EIPICO) is a leading pharmaceutical company in Egypt that produces a wide range of therapeutic products, including those for liver disease
Delta Pharma: Delta Pharma is an Egyptian pharmaceutical company that produces a variety of therapeutics, including those for liver disease
Memphis Pharmaceutical and Chemical Industries: Memphis Pharmaceutical and Chemical Industries is an Egyptian pharmaceutical company that develops and produces a range of therapeutic products, including those for liver disease
Pharco Pharmaceuticals: Pharco Pharmaceuticals is an Egyptian pharmaceutical company that produces a range of therapeutics, including those for liver disease
Amoun Pharmaceutical Company: Amoun Pharmaceutical Company is an Egyptian pharmaceutical company that develops and produces a wide range of therapeutic products, including those for liver disease

Healthcare Policies and Reimbursement Scenarios

Egypt approved the Universal Health Insurance (UHI) bill in 2018 to attain universal health coverage as part of Transforming Egypt's Healthcare System Project. The goal of the UHI law is to cover the entire population by securing money through innovative and diverse finance channels. The adoption of Egypt's UHI law shows the country's progress toward universal health care, and it is the culmination of extensive and concerted efforts by the Egyptian government and major stakeholders, including the World Health Organization (WHO). The Egyptian Drug Authority (EDA) and the Ministry of Health and Population oversee the regulation and reimbursement of liver treatments in Egypt.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.